Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis-Reference-Cited by-同舟云学术

Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis

Published:2022-02 Issue:2 Volume:28 Page:104.e1-104.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Takahashi Takuto^ORCID,Illamola Sílvia M.^ORCID,Jennissen Cathryn A.^ORCID,Long Susan E.,Lund Troy C.,Orchard Paul J.^ORCID,Gupta Ashish O.^ORCID,Long-Boyle Janel R.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference39 articles.

1. Personalizing Busulfan-Based Conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee;Palmer;Biol Blood Marrow Transplant,2016

2. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis;Bartelink;Lancet Haematol,2016

3. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients;Ljungman;Bone Marrow Transplant,1997

4. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children;Huezo-Diaz;Curr Drug Metab,2014

5. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen;Geddes;Biol Blood Marrow Transplant,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations;Clinical Pharmacokinetics;2023-07

2. Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR;European Journal of Haematology;2022-12

3. Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation;Pharmaceutics;2022-05-27